Stockpolly
Search
EPRX · NASDAQ · Biotechnology

Eupraxia Pharmaceuticals (EPRX)

Develops locally delivered, extended-release drug candidates using its Diffusphere microsphere technology.

$7.40
Pre-market−0.04 (−0.54%)
At close$7.44(+17.35%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
695767787161618
Research & development48344445481113
312323332855
General & administrative312320332855
Other expenses000000000000
Operating income−6−9−5−7−6−7−7−8−7−16−16−18
210000001−134
Interest income000000000111
Interest expense000000000000
Other non-operating income−2−1−1−10000−11−3−4
Income before tax−5−8−5−6−6−7−7−9−6−17−13−14
Income tax expense000000000000
Net income from continuing operations−5—−5−6−6−7−7−9−6−17−13−14
Net income−5−8−4−6−6−7−7−9−6−17−13−14
EPS, basic−$0.41−$0.11−$0.15−$0.17−$0.17−$0.20−$0.21−$0.24−$0.19−$0.34−$0.23−$0.23
EPS, diluted−$0.41−$0.11−$0.15−$0.17−$0.17−$0.20−$0.21−$0.24−$0.19−$0.34−$0.23−$0.23
Weighted average shares, basic272429363636363637525766
Weighted average shares, diluted272429363636363637525766
EBITDA−4−8−4−6−6−7−7−9−6−17−13−14
Depreciation & amortization000000000000
EBIT−4−8−4−6−6−7−7−9−6−17−13−14